Xtant Medical Holdings, Inc.
XTNT · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.27 | 0.00 | -2.86 | 0.13 |
| FCF Yield | 4.63% | 0.88% | 0.13% | -0.01% |
| EV / EBITDA | 26.19 | 22.27 | 44.95 | -105.00 |
| Quality | ||||
| ROIC | 2.56% | 5.04% | 1.36% | -2.41% |
| Gross Margin | 66.13% | 68.58% | 61.52% | 50.85% |
| Cash Conversion Ratio | 3.53 | 0.36 | 22.03 | -0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.26% | 23.45% | 24.78% | 26.47% |
| Free Cash Flow Growth | 359.56% | 945.98% | 1,342.86% | 99.82% |
| Safety | ||||
| Net Debt / EBITDA | 1.29 | 5.04 | 13.60 | -33.58 |
| Interest Coverage | 2.81 | 4.61 | 1.02 | -1.66 |
| Efficiency | ||||
| Inventory Turnover | 0.28 | 0.28 | 0.33 | 0.40 |
| Cash Conversion Cycle | 339.61 | 334.70 | 289.49 | 237.48 |